| PLIANT THERAPEUTICS, INC. |
Director |
Common Stock (Right to Buy) |
30,000 |
$55,669 |
$2.08 |
05 Jun 2025 |
Direct |
| Pyxis Oncology, Inc. |
Director |
Stock Option (Right to Buy) |
36,979 |
$36,239 |
$0.9800 |
31 Mar 2025 |
Direct |
| Xenon Pharmaceuticals Inc. |
Chief Commercial Officer |
Share Option (Right to Buy) |
40,000 |
|
|
09 Jan 2026 |
Direct |
| Xenon Pharmaceuticals Inc. |
Chief Commercial Officer |
Restricted Share Units |
20,000 |
|
|
09 Jan 2026 |
Direct |
| IMPEL PHARMACEUTICALS INC |
Director |
Stock Option (right to buy) |
13,222 |
|
|
16 Jun 2023 |
Direct |
| GW PHARMACEUTICALS PLC |
U.S. Chief Commercial Officer |
Ordinary Shares |
0 |
|
|
05 May 2021 |
Direct |
| GW PHARMACEUTICALS PLC |
U.S. Chief Commercial Officer |
Share Options |
0 |
|
|
05 May 2021 |
Direct |
| IMPEL PHARMACEUTICALS INC |
Director |
No securities beneficially held. |
0 |
|
|
12 Apr 2023 |
Direct |
| Xenon Pharmaceuticals Inc. |
Chief Commercial Officer |
No securities are beneficially owned. |
0 |
|
|
23 Jun 2025 |
Direct |